|
1
|
Gu Q, Paulose-Ram R, Burt VL and Kit BK:
Prescription cholesterol-lowering medication use in adults aged 40
and over: United States, 2003–2012. National Center for Health
Statistics. 2014. NCHS Data Brief. 177:1–8. 2014.
|
|
2
|
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL,
Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, et
al: The effect of pravastatin on coronary events after myocardial
infarction in patients with average cholesterol levels. Cholesterol
and Recurrent Events Trial investigators. N Engl J Med.
335:1001–1009. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Long-Term Intervention with Pravastatin in
Ischaemic Disease (LIPID) Study Group, : Prevention of
cardiovascular events and death with pravastatin in patients with
coronary heart disease and a broad range of initial cholesterol
levels. N Engl J Med. 339:1349–1357. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Serruys PW, de Feyter P, Macaya C, Kokott
N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B,
et al Lescol Intervention Prevention Study (LIPS) Investigators, :
Fluvastatin for prevention of cardiac events following successful
first percutaneous coronary intervention: A randomized controlled
trial. JAMA. 287:3215–3222. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wong ND, Young D, Zhao Y, Nguyen H,
Caballes J, Khan I and Sanchez RJ: Prevalence of the American
College of Cardiology/American Heart Association statin eligibility
groups, statin use, and low-density lipoprotein cholesterol control
in US adults using the National Health and Nutrition Examination
Survey 2011–2012. J Clin Lipidol. 10:1109–1118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan KK, Oza AM and Siu LL: The statins as
anticancer agents. Clin Cancer Res. 9:10–19. 2003.PubMed/NCBI
|
|
7
|
Ishikawa S, Hayashi H, Kinoshita K, Abe M,
Kuroki H, Tokunaga R, Tomiyasu S, Tanaka H, Sugita H, Arita T, et
al: Statins inhibit tumor progression via an enhancer of zeste
homolog 2-mediated epigenetic alteration in colorectal cancer. Int
J Cancer. 135:2528–2536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bardou M, Barkun A and Martel M: Effect of
statin therapy on colorectal cancer. Gut. 59:1572–1585. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wong WW, Dimitroulakos J, Minden MD and
Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: The
statin family of drugs as triggers of tumor-specific apoptosis.
Leukemia. 16:508–519. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Keyomarsi K, Sandoval L, Band V and Pardee
AB: Synchronization of tumor and normal cells from G1 to multiple
cell cycles by lovastatin. Cancer Res. 51:3602–3609.
1991.PubMed/NCBI
|
|
11
|
Mehta N, Hordines J, Sykes D, Doerr RJ and
Cohen SA: Low density lipoproteins and Lovastatin modulate the
organ-specific transendothelial migration of primary and metastatic
human colon adenocarcinoma cell lines in vitro. Clin Exp
Metastasis. 16:587–594. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Simon MS, Rosenberg CA, Rodabough RJ,
Greenland P, Ockene I, Roy HK, Lane DS, Cauley JA and Khandekar J:
Prospective analysis of association between use of statins or other
lipid-lowering agents and colorectal cancer risk. Ann Epidemiol.
22:17–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Poynter JN, Gruber SB, Higgins PD, Almog
R, Bonner JD, Rennert HS, Low M, Greenson JK and Rennert G: Statins
and the risk of colorectal cancer. N Engl J Med. 352:2184–2192.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lytras T, Nikolopoulos G and Bonovas S:
Statins and the risk of colorectal cancer: an updated systematic
review and meta-analysis of 40 studies. World J Gastroenterol.
20:1858–1870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bonovas S, Filioussi K, Tsavaris N and
Sitaras NM: Statins and cancer risk: A literature-based
meta-analysis and meta-regression analysis of 35 randomized
controlled trials. J Clin Oncol. 24:4808–4817. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bonovas S, Filioussi K, Flordellis CS and
Sitaras NM: Statins and the risk of colorectal cancer: A
meta-analysis of 18 studies involving more than 1.5 million
patients. J Clin Oncol. 25:3462–3468. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cai H, Zhang G, Wang Z, Luo Z and Zhou X:
Relationship between the use of statins and patient survival in
colorectal cancer: A systematic review and meta-analysis. PLoS One.
10:e01269442015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gray RT, Coleman HG, Hughes C, Murray LJ
and Cardwell CR: Statin use and survival in colorectal cancer:
Results from a population-based cohort study and an updated
systematic review and meta-analysis. Cancer Epidemiol. 45:71–81.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cardwell CR, Hicks BM, Hughes C and Murray
LJ: Statin use after colorectal cancer diagnosis and survival: A
population-based cohort study. J Clin Oncol. 32:3177–3183. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Siddiqui AA, Nazario H, Mahgoub A, Patel
M, Cipher D and Spechler SJ: For patients with colorectal cancer,
the long-term use of statins is associated with better clinical
outcomes. Dig Dis Sci. 54:1307–1311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seasholtz TM, Majumdar M and Brown JH: Rho
as a mediator of G protein-coupled receptor signaling. Mol
Pharmacol. 55:949–956. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Holstein SA, Wohlford-Lenane CL and Hohl
RJ: Isoprenoids influence expression of Ras and Ras-related
proteins. Biochemistry. 41:13698–13704. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Denoyelle C, Vasse M, Körner M, Mishal Z,
Ganné F, Vannier JP, Soria J and Soria C: Cerivastatin, an
inhibitor of HMG-CoA reductase, inhibits the signaling pathways
involved in the invasiveness and metastatic properties of highly
invasive breast cancer cell lines: An in vitro study.
Carcinogenesis. 22:1139–1148. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sleijfer S, van der Gaast A, Planting AS,
Stoter G and Verweij J: The potential of statins as part of
anti-cancer treatment. Eur J Cancer. 41:516–522. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nübel T, Dippold W, Kleinert H, Kaina B
and Fritz G: Lovastatin inhibits Rho-regulated expression of
E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J.
18:140–142. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC
and Song IS: Simvastatin induces apoptosis in human colon cancer
cells and in tumor xenografts, and attenuates colitis-associated
colon cancer in mice. Int J Cancer. 123:951–957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Anderson GL, Manson J, Wallace R, Lund B,
Hall D, Davis S, Shumaker S, Wang CY, Stein E and Prentice RL:
Implementation of the women's health initiative study design. Ann
Epidemiol. 13 (Suppl):S5–S17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Langer RD, White E, Lewis CE, Kotchen JM,
Hendrix SL and Trevisan M: The Women's Health Initiative
Observational Study: Baseline characteristics of participants and
reliability of baseline measures. Ann Epidemiol. 13
(Suppl):S107–S121. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Women's Health Initiative: About WHI.
https://www.whi.org/about/SitePages/About%20WHI.aspxMay
13–2019
|
|
30
|
Schachter M: Chemical, pharmacokinetic and
pharmacodynamic properties of statins: An update. Fundam Clin
Pharmacol. 19:117–125. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Desai P, Lehman A, Chlebowski RT, Kwan ML,
Arun M, Manson JE, Lavasani S, Wasswertheil-Smoller S, Sarto GE,
LeBoff M, et al: Statins and breast cancer stage and mortality in
the Women's Health Initiative. Cancer Causes Control. 26:529–539.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maringe C, Walters S, Rachet B, Butler J,
Fields T, Finan P, Maxwell R, Nedrebø B, Påhlman L, Sjövall A, et
al ICBP Module 1 Working Group, : Stage at diagnosis and colorectal
cancer survival in six high-income countries: A population-based
study of patients diagnosed during 2000–2007. Acta Oncol.
52:919–932. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nayak J and Goel S: Revised TNM staging
for colorectal cancer: Did we miss the golden opportunity to do
right by the staging? Clin Colorectal Cancer. 10:207–209. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Katz MS, Minsky BD, Saltz LB, Riedel E,
Chessin DB and Guillem JG: Association of statin use with a
pathologic complete response to neoadjuvant chemoradiation for
rectal cancer. Int J Radiat Oncol Biol Phys. 62:1363–1370. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mace AG, Gantt GA, Skacel M, Pai R, Hammel
JP and Kalady MF: Statin therapy is associated with improved
pathologic response to neoadjuvant chemoradiation in rectal cancer.
Dis Colon Rectum. 56:1217–1227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ng K, Ogino S, Meyerhardt JA, Chan JA,
Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB
III, et al: Relationship between statin use and colon cancer
recurrence and survival: Results from CALGB 89803. J Natl Cancer
Inst. 103:1540–1551. 2011. View Article : Google Scholar : PubMed/NCBI
|
